» Articles » PMID: 15750970

[The Hemodiafiltration with Endogenous Reinfusion Reduces the Erythroid Progenitor Inhibition by Uremic Serum]

Overview
Journal G Ital Nefrol
Specialty Nephrology
Date 2005 Mar 8
PMID 15750970
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Anemia in end-stage renal disease (ESRD) patients shows a lower proliferation of erythroid progenitor cells such as burst forming unit-erythroid (BFU-E) than in normal subjects. As on-line hemodiafiltration with endogenous reinfusion(HFR) is thought to have a better biocompatibility and a wide range of uremic toxin removal, we compared the effect of serum obtained pre- and post-standard hemodialysis (HD) and HFR dialysis performed in four ESRD patients with proliferation in normal subject) (controls) bone marrow BFU-E.

Methods: Mononuclear fraction was obtained by Ficoll-Hypaque density centrifugation and studies were performed in three different conditions: standard culture, adding serum from controls, adding serum from ESRD patients pre- and post HD and HFR dialysis. BFU-E were counted after 14 days with an inverted microscope and expressed as average scores from two dishes. Standardization between experiments was checked with a control culture for each experimental culture.

Results: The BFU-E proliferation rate was clearly reduced by adding serum from ESRD patients either pre-HD or pre-HFR. However, while this inhibition was exacerbated by post-HD serum, it showed a significant reduction with post-HFR serum.

Conclusions: This effect could be due to the removal of uremic toxins or to a lower dialysis-induced cytokine release, both mechanisms involved in erythropoiesis inhibition in ESRD.

Citing Articles

Gut Dysbiosis and Its Role in the Anemia of Chronic Kidney Disease.

Coll E, Cigarran S, Portoles J, Cases A Toxins (Basel). 2024; 16(11).

PMID: 39591250 PMC: 11598790. DOI: 10.3390/toxins16110495.


Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease.

Hsieh C, Chan M, Su Y, Fu J, Wang I, Chen C Healthcare (Basel). 2021; 9(11).

PMID: 34828498 PMC: 8621268. DOI: 10.3390/healthcare9111452.